Format

Send to

Choose Destination
Cancer Discov. 2015 Mar;5(3):234-6. doi: 10.1158/2159-8290.CD-15-0095.

Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies.

Author information

1
Institute for Cancer Genetics, Columbia University, New York, New York.
2
Institute for Cancer Genetics, Columbia University, New York, New York. Department of Pathology, Columbia University Medical Center, New York, New York. Department of Pediatrics, Columbia University Medical Center, New York, New York. af2196@columbia.edu.

Abstract

Kleppe and colleagues use detailed cytokine profiling analyses to investigate the role of aberrant proinflammatory cytokine secretion in the pathogenesis of myeloproliferative neoplasms. Their analyses implicate constitutive activation of STAT3 in both malignant and nonmalignant bone marrow cell populations as a driver of aberrant cytokine secretion and as a cellular target mediating the therapeutic activity of ruxolitinib.

PMID:
25749974
PMCID:
PMC4355913
DOI:
10.1158/2159-8290.CD-15-0095
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center